Baker & Eastlack Ventures
Baker & Eastlack Ventures
  • Home
  • About
  • Portfolio
  • Investment Focus
  • News
  • Contact
October 2 2019

ControlRad™ Secures $15 Million Series B Financing, Expands Board of Directors

Financing Round Led by Questa Capital to Fuel Commercialization of ControlRad Trace Mobile C-arm Radiation Reduction Technology

Medical Device Industry Veterans Ryan Drant and Tim Patrick Join Board

ATLANTA, October 2, 2019 – ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures (FGP), today announced it completed $15 million in financing and that medical device industry veterans Ryan Drant  and Tim Patrick have joined its board of directors. The Series B round, which was led by Questa Capital, will be used for fueling the commercial launch of the innovative ControlRad Trace system. 

Read the full article here: https://www.controlrad.com/our-news/87-controlrad-secures-15-million-series-b-financing-expands-board-of-directors

 

CMS now covers Clarify’s phototherapy psoriasis treatment With smartphone-connected home light therapy, Clarify Medical breaks new ground in psoriasis

Related Posts

Uncategorized

Micron Medical Appoints Seasoned Healthcare Executive Mark Landy as Chief Executive Officer

Uncategorized

Zerigo Now Approved as a MultiPlan Participating Provider

Uncategorized

Spinal Singularity Hires New CEO

Baker & Eastlack Ventures

Contact Us

Email: bakerandeastlack@gmail.com

© Baker & Eastlack Ventures 2025